Pilgrim Partners Asia Pte Ltd bought a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 18,800 shares of the company's stock, valued at approximately $392,000.
A number of other institutional investors have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its holdings in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares during the period. Lindbrook Capital LLC increased its holdings in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after acquiring an additional 950 shares during the period. GAMMA Investing LLC increased its position in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after buying an additional 1,051 shares in the last quarter. Cromwell Holdings LLC raised its stake in Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after acquiring an additional 2,496 shares during the last quarter. Finally, R Squared Ltd purchased a new position in shares of Genmab A/S during the 4th quarter valued at about $93,000. Institutional investors own 7.07% of the company's stock.
Genmab A/S Stock Performance
Genmab A/S stock traded down $1.07 during midday trading on Thursday, reaching $17.77. The stock had a trading volume of 1,129,237 shares, compared to its average volume of 1,008,106. The firm's fifty day simple moving average is $20.51 and its 200-day simple moving average is $21.38. The stock has a market capitalization of $11.76 billion, a P/E ratio of 10.21, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.41.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
GMAB has been the topic of a number of research analyst reports. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a research report on Thursday, February 13th. HC Wainwright restated a "buy" rating and set a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Finally, Truist Financial cut their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $39.17.
View Our Latest Research Report on Genmab A/S
Genmab A/S Company Profile
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
